Xencor Inc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $XNCR in the last 30 days.
See all $XNCR insider activity →Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.
RBC Capital maintained an Outperform rating on Xencor with a $43 price target, implying a 47.4% upside. The firm cited strong clinical data for XmAb819 and Xencor's robust pipeline as reasons for the target.
Wedbush kept its Outperform rating on Xencor with a $45 price target, suggesting 54.2% upside from the last close. XmAb819 showed 45% ORR in ccRCC trials, supporting accelerated approval. Xencor plans global studies and FDA discussions for market share.
Over the past 7 days, AlphAI's AI scored 23 news stories mentioning XNCR (Xencor Inc). Coverage has skewed bullish: 21 bullish, 2 neutral, and 0 bearish.
Recent XNCR coverage spans financial news, technology and market movers.
Positive trial data likely drives share price higher.
Positive trial data and higher price target suggest upside potential.
Analyst upgrade and strong trial data suggest significant upside.
Analyst upgrades and strong trial data suggest near‑term upside for Xencor.
The filing provides no material details, so immediate price impact is uncertain.
AlphAI scores every news story that mentions XNCR with an AI model for sentiment and relevance, and aggregates insider trades from Xencor Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.
2 min readRBC Capital maintained an Outperform rating on Xencor with a $43 price target, implying a 47.4% upside. The firm cited strong clinical data for XmAb819 and Xencor's robust pipeline as reasons for the target.
2 min readWedbush kept its Outperform rating on Xencor with a $45 price target, suggesting 54.2% upside from the last close. XmAb819 showed 45% ORR in ccRCC trials, supporting accelerated approval. Xencor plans global studies and FDA discussions for market share.
1 min readWells Fargo raised its price target for Xencor (NASDAQ:XNCR) to $44 from $30, citing positive kidney cancer trial data. The stock has gained 105% over the past year and trades at $29.18. Analysts highlight potential for further gains through 2026. Other analysts, including RBC and Truist, also increased their price targets.
2 min readXencor, Inc. (XNCR) filed an 8-K form with the SEC on October 26, 2026, disclosing corporate changes and voting matters. The filing includes exhibits related to the changes.
1 min readSurgery Partners (SGRY) rose 48% on $6B buyout talks with Bon Secours Mercy Health. Xencor (XNCR) gained 17% on positive Phase 1 kidney cancer data. Oruka (ORKA) jumped 12% after strong Phase 2b psoriasis results. Acumen (ABOS) rose 19% ahead of November Alzheimer's trial readout.
2 min readXencor (XNCR) stock rose 15.9% after presenting Phase 1 data for XmAb819, showing a 45.5% response rate and 82% six-month survival. The company plans FDA discussions for accelerated approval and a Phase 3 study. Analysts maintain positive ratings with targets at $29-$30. XNCR's cash is expected to last into 2029.
2 min readXencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ® Designing Proteins Delivering Medicines Updated Results from Dose Expansion Cohorts in the Phase 1 Study of XmAb819 October 26, 2026 2 Today's Speakers Bassil Dahiyat, Ph.D. President & Chief Executive Officer Xencor Management Guest Speaker Sumanta Pal, M.D., F.A.
2 min readU.S. stock futures stabilized Monday. Xencor (XNCR) shares rose 23.94% after reporting positive clinical trial results for its drug candidate, according to the company.
1 min readSpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.
3 min read
